PHS81 Surgery And Biologic Use Pattern For Ulcerative Colitis Patients Initiated With Infliximab In A Managed Care Setting In The United States  by Muszka, J. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A199 
 
 
generic utilization 72.2% of the claims (range=66.1%-84.8%). The average price of 
generic drug was $17.44 (range=$6.25-$29.12), while the average price of brand 
drugs was $217.07 (range=$105.63-$357.51). The average pharmacy dispensing fee 
was $4.51±$2.03 for generics and $4.26±$2.03 for brands (range for both=$1.75-
$11.50). The ingredient cost was estimated using average wholesaler price (AWP) 
(n=25), wholesaler acquisition cost (WAC, n=11) and combination AWP/WAC 
(n=10). We found no statistical significant relationship between the number of 
claims or the total state expenditures, and the dispensing fee or ingredient cost. 
CONCLUSIONS: Dispensing fees and ingredient cost varied among the different 
states’ Medicaid programs. Those differences were not related to the total 
utilization and expenditures of the state programs. Appropriate reimbursement 
and dispensing fee policies encouraging generic utilization could result in 
substantial saving for the Medicaid program.  
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OBJECTIVES: As the health care safety net continues to grow in both depth and 
breadth, the provider payment system will play an increasing role in the 
resource allocation of health care in China. This paper is intended to assess the 
primary effects of payment reform of capitation experiment and the 
supplementary open enrollment policy in Changde city, China. METHODS: In 
October 2007, Changde employed a capitation approach to pay for health care 
under the Urban Resident Basic Medical Insurance (URBMI), while the fee-for-
service approach was still used by the Urban Employee Basic Medical Insurance 
(UEBMI) in the city and other programs as well. Using the national URBMI 
Household Panel Survey from 2008-2010, we conducted a set of difference-in-
difference (DD) models to assess the capitation policy effect on cost and 
utilization outcomes while controlling for other differences between Changde 
and other cities. RESULTS: The study finds the payment reform to reduce its 
inpatient out-of-pocket cost by 19.7%, out-of-pocket ratio by 9.5%, and length of 
stay by 17.5%. The total inpatient cost, drug cost ratio, treatment effect, and 
patient satisfaction showed little difference between FFS and capitation models. 
The robust tests find the relatively poor health subsample present a similar 
pattern with the results based on the full sample; as for the population cohort 
with good and very good self-rated health conditions, the payment reform in 
Changde has little impact on either providers or patients. CONCLUSIONS: We 
conclude that the payment reform in Changde led to an decrease in the financial 
burden of patients for inpatient care and improve hospital efficiency, without 
compromising quality of care. The total cost measures remain no change 
between capitation and FFS settings, which can be research topics for further 
studies concerning the long term effect of capitation approaches.  
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OBJECTIVES: To investigate treatment patterns of glaucoma and persistence to 
therapy in a large health organization (HMO) in Israel. METHODS: A retrospective 
cohort study, conducted using the electronic medical databases of Maccabi 
Healthcare Services, a 2 million member HMO in Israel. The study population 
consisted of all patients who were newly diagnosed with glaucoma between 2003 
and 2010 at MHS. Collected data included personal characteristics and 
demographics, relevant surgical procedures, prescribed and dispensed anti-
glaucoma medications, and caregiver characteristics. We investigated quality of 
care indices including routine ophthalmologist follow up, performance of 
tonometry tests, as well as persistence to treatment by drug type. Persistence 
was analyzed by proportion of days covered by drugs during follow up time, 
ignoring overlaps due to overuse and simultaneous combination of several types 
of eye drops. RESULTS: A total of 11,512 incident glaucoma patients, who were 
diagnosed between 2003 and 2010 were identified. One quarter of these patients 
remained naïve through the follow-up period, additional 20% were non-adherent 
with therapy (covered less than 20% of the follow up time), and only 13% 
exhibited high persistence (covered at least 80% of the follow-up period). The 
most common physician was ophthalmologist both at treatment initiation (70% 
of initial prescriptions were ophthalmologist vs. 7% by general practitioner) and 
ongoing prescriptions (48% ophthalmologist vs. 22% by general practitioner). 
CONCLUSIONS: The current study demonstrates the potential use of automated 
medical databases to characterize treatment patterns of glaucoma, illustrate the 
great variety of drug therapies, and describe adherence to treatment in the 
community. The increased comorbidity and mortality among these patients has 
important implication for health authorities for prevention and delivery of 
health-care services.  
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OBJECTIVES: To investigate outpatients' knowledge, attitude and awareness 
on medication and analyze the influential factors. METHODS: A total of 711 
outpatients who consented to participate the survey were recruited from 306 
Hospital of PLA in Beijing between 2009-2012. The self-administered question-
naire was composed of XX questions. Multiple linear regressions were run to 
explore the influential factors. Data were analyzed using STATA v11.0. 
RESULTS: The outpatients investigated showed a poor cognition on rational 
drug use. 84.8% of the patients would stop taking drugs by themselves. 60.1% 
of the patients were aware of adverse drug reactions. Age, urban-rural 
difference, knowledge of medication, and health status have different degrees 
of influence on the medication behavior and medication willingness of 
patients, while family income and health insurance have little influence. 
Information provided by the patients was compared with the prescriptions. 
CONCLUSIONS: These results suggest that outpatients in China had much 
misunderstanding about drug use. Patients’ education regarding rational  
drug use is an important issue and deserves urgent improvement. KEY 
WORDS: Outpatients; Cognition; Determin-ants; Rational use of drug; Self-
medication.  
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OBJECTIVES: To determine patient demographics and treatment patterns  
in patients with Crohn’s Disease (CD) who initiated biologic treatment with a 
TNF antagonist (infliximab or adalimumab). METHODS: Patients ≥ 18 years with 
CD (ICD-9:555.X) who initiated a TNF antagonist between January 2007 and  
December 2008 were identified from the US IMPACT health insurance claims 
data-base. Two cohorts were identified; those who received CD related surgery 
(CDSURG) within a 24-month follow-up and those who did not (CDNon-SURG). 
Patients continuously enrolled for medical and pharmacy benefits during 6 
months prior to their first TNF antagonist claim (index claim). RESULTS: A  
total of 812 individuals with CD were followed over a 24-month period, of which 
92% were CDNon-SURG and 8% were CDSURG patients. The majority of patients 
(89%) were 18 to 54 years old with a higher portion of CDSURG patients in the 18-
34 age range. CDSURG included younger patients (mean age: 37 yrs) and a lower 
percent of females (48%) compared to CDNon-SURG (41 yrs; 59% female). 
CDSURG patients had higher hospitalization rates (38%) and incurred more 
health care expenditures ($15,112) during baseline compared to CDNon-SURG 
patients (23%; $13,400). During the last 6 months of follow-up, the percentage of 
CDSURG patients on biologics dropped to 44%; of the 56% in CDSURG who 
discontinued biologics, 31% received no treatment. In contrast, the percentage of 
CDNon-SURG patients continuing biologics decreased to 67% with 37% remaining 
on a “biologic only.” CONCLUSIONS: Most CD patients (92%) initiated on biologics 
did not require surgery, however about one third stopped TNF antagonist 
treatment over 24 months. Although 8% of CD patients underwent surgery, they 
incurred high direct and indirect costs even prior to surgery. Even with 
availability of TNF antagonists, due to high discontinuation rate, there is an 
unmet need of effective CD treatment options that may delay or prevent disease 
progression.  
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OBJECTIVES: To identify patient demographics and treatment use patterns in 
patients with Ulcerative Colitis (UC) who initiated biologic treatment with 
infliximab in a managed care setting. METHODS: Patients with UC (ICD-9 code 
556.X) who initiated infliximab between January 2007 and December 2008 were 
identified from the US IMPACT health insurance claims database. Two cohorts 
were identified based on whether they received UC related surgery (UCSURG) or 
did not receive a UC related surgery (UCNon-SURG) within a 24 month follow-up. 
All patients were continuously enrolled for both medical and pharmacy benefits 
during the 6 months prior to their first infliximab claim (index claim) and 24 
months post index claim. RESULTS: A total of 264 individuals with UC were 
followed over 24-months, of which 84% did not receive surgery (UCNon-SURG) 
and 16% underwent surgery (UCSURG). In both cohorts, mean age was 42 years 
and 45% were women. The majority of patients (80%) were 18 to 54 years old 
with a higher proportion of UCSURG patients in the 35-44 year group range. 
During the 6-month baseline period, UCSURG patients had higher hospitalization 
rates (40%) and incurred more health care expenditures ($17,217) than UCNon-
SURG (22%; $11,774). In the 24 month follow-up, 60% of patients within UCSURG 
underwent surgery during the first year following their index claim. Seventy 
percent of UCNon-SURG patients continued biologics with 34% remaining  
on “biologic only” compared to UCSURG, where 70% had no treatment. 
CONCLUSIONS: Most UC patients (84%) initiated on infliximab did not require 
surgery and continued biologic treatment (70%) over 24 months. Additional 
research is needed to further understand reasons for discontinuation of  
biologic treatment. Although 16% of UC patients underwent surgery, they 
incurred high direct and indirect costs even prior to surgery. There is an unmet 
need of effective UC treatment options that may delay or prevent disease 
progression.  
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